News
Bond Biosciences, Inc. to Present at Biotech Showcase™ 2024
January 4th, 2024
Dr. Cory Berkland, PhD will be presenting on behalf of Bond Biosciences to provide a corporate update and results from a Phase 1b trial evaluating BBI-001.
Bond Biosciences Announces Positive Phase Ia/b Pharmacodynamic and Safety Data for BBI-001, a Novel, Non-Absorbed, Oral Therapy for Iron Overload
July 20th, 2023
BBI-001 was well tolerated with no dose limiting toxicities.
Single-dose administration demonstrated a statistically significant reduction of dietary iron absorption.
Bond Biosciences Announces First Dosing of Sentinel Patients in a Phase Ia/b Clinical Trial for a Novel Therapy to Treat Patients with Hemochromatosis
April 5th, 2022
This trial is a first-in-human Phase Ia/b Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study Enrolling Healthy Anemic and Hemochromatosis patients across three cohorts to assess safety, tolerability, and pharmacodynamic effect of BBI-001.
Bond Biosciences Announces
Closing of Series B Financing
January 25th, 2022
Company completes a Series B financing to enable accelerated manufacturing timelines for BBI-001 and pipeline development.
Bond Biosciences Announces
Closing of Series A Financing
March 30th, 2021
Company completes Series A financing to enable Phase 1b studies for lead candidate BBI-001 in patients with Hereditary Hemochromatosis.